These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

759 related articles for article (PubMed ID: 17543074)

  • 1. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential.
    O'Neill CJ; McBride HA; Connolly LE; McCluggage WG
    Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential expression of P16 and P21 in benign and malignant uterine smooth muscle tumors.
    Ünver NU; Acikalin MF; Öner Ü; Ciftci E; Ozalp SS; Colak E
    Arch Gynecol Obstet; 2011 Aug; 284(2):483-90. PubMed ID: 20878171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathologic analysis of 16 cases.
    Ip PP; Cheung AN; Clement PB
    Am J Surg Pathol; 2009 Jul; 33(7):992-1005. PubMed ID: 19417585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis.
    Bodner-Adler B; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
    Gynecol Oncol; 2005 Jan; 96(1):62-6. PubMed ID: 15589581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P16, Ki67, P53, and WT1 Expression in Uterine Smooth Muscle Tumors: An Adjunct in Confirming the Diagnosis of Malignancy in Ambiguous Cases.
    Delgado B; Dreiher J; Braiman D; Meirovitz M; Shaco-Levy R
    Int J Gynecol Pathol; 2021 May; 40(3):257-262. PubMed ID: 32897968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Progress in clinicopathologic study on uterine smooth muscle tumor of uncertain malignant potential].
    Deng ZJ; Guo LN
    Zhonghua Bing Li Xue Za Zhi; 2011 Aug; 40(8):573-6. PubMed ID: 22169655
    [No Abstract]   [Full Text] [Related]  

  • 7. EMMPRIN (CD147) Expression in Smooth Muscle Tumors of the Uterus.
    Kefeli M; Yildiz L; Gun S; Ozen FZ; Karagoz F
    Int J Gynecol Pathol; 2016 Jan; 35(1):1-7. PubMed ID: 26352545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of MCM2 With Ki67 and p16 Immunohistochemistry Can Distinguish Uterine Leiomyosarcomas.
    Keyhanian K; Lage JM; Chernetsova E; Sekhon H; Eslami Z; Islam S
    Int J Gynecol Pathol; 2020 Jul; 39(4):354-361. PubMed ID: 32515921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors.
    Mittal K; Demopoulos RI
    Hum Pathol; 2001 Sep; 32(9):984-7. PubMed ID: 11567229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic value of progesterone receptor, p16, p53 and pHH3 expression in uterine atypical leiomyoma.
    Liang Y; Zhang X; Chen X; Lü W
    Int J Clin Exp Pathol; 2015; 8(6):7196-202. PubMed ID: 26261614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fascin expression in uterine smooth muscle tumors.
    Kefeli M; Yildiz L; Kaya FC; Aydin O; Kandemir B
    Int J Gynecol Pathol; 2009 Jul; 28(4):328-33. PubMed ID: 19483633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
    Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
    J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical Uterine Smooth Muscle Tumors: A Retrospective Evaluation of Clinical and Pathologic Features.
    Maltese G; Fontanella C; Lepori S; Scaffa C; Fucà G; Bogani G; Provenzano S; Carcangiu ML; Raspagliesi F; Lorusso D
    Oncology; 2018; 94(1):1-6. PubMed ID: 28869928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An immunohistochemical analysis of stathmin 1 expression in uterine smooth muscle tumors: differential expression in leiomyosarcomas and leiomyomas.
    Allen MM; Douds JJ; Liang SX; Desouki MM; Parkash V; Fadare O
    Int J Clin Exp Pathol; 2015; 8(3):2795-801. PubMed ID: 26045786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of thrombospondin 1 (TSP 1) in patients with uterine smooth muscle tumors: an immunohistochemical study.
    Bodner-Adler B; Nather A; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
    Gynecol Oncol; 2006 Oct; 103(1):186-9. PubMed ID: 16595146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Immunoreactivity of p16 in leiomyosarcomas and leiomyoma variants.
    Gannon BR; Manduch M; Childs TJ
    Int J Gynecol Pathol; 2008 Jan; 27(1):68-73. PubMed ID: 18156978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors.
    Chen L; Yang B
    Int J Gynecol Pathol; 2008 Jul; 27(3):326-32. PubMed ID: 18580309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of Ki-67, P53 and progesterone receptors in uterine smooth muscle tumors. Diagnostic value.
    Petrović D; Babić D; Forko JI; Martinac I
    Coll Antropol; 2010 Mar; 34(1):93-7. PubMed ID: 20437637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoexpression of p16 in uterine leiomyomas with infarct-type necrosis: an analysis of 35 cases.
    Ip PP; Lim D; Cheung ANY; Oliva E
    Histopathology; 2017 Nov; 71(5):743-750. PubMed ID: 28609585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors.
    Lee CH; Turbin DA; Sung YC; Espinosa I; Montgomery K; van de Rijn M; Gilks CB
    Mod Pathol; 2009 Dec; 22(12):1519-31. PubMed ID: 19734847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.